CAM 1481
Latest Information Update: 28 Oct 1997
At a glance
- Originator Pfizer
- Class Antineoplastics
- Mechanism of Action Cholecystokinin A receptor antagonists; Cholecystokinin B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Oct 1997 No-Development-Reported for Cancer in Australia (Unknown route)
- 17 Jan 1995 Preclinical development for Cancer in Australia (Unknown route)